Abiopharma

🔍 Williams Laura A (Executive)

Company: ARDELYX, INC. (ARDX)

Report Date: 2025-08-26

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Common Stock at $0.99 per share (Direct)
  Date: 2025-08-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 446,322.00 | transaction_form_type: 4
• Sold 50,000 shares of Common Stock at $6.121 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 396,322.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 30,000 shares of Common Stock at $6.121 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 366,322.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,000 shares of Stock Option (Right to Buy) at $0.99 per share (Derivative)
  Date: 2025-08-26 | Code: M | Expires: 2032-01-06 | equity_swap_involved: 0 | shares_owned_after: 112,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: This transaction was executed in multiple trades in prices ranging from $6.04 to $6.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F2: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.